New findings highlight the lingering issue of gender inequity in the field, the effects of which extend well beyond career growth for women. 

Promoting preventive care among young adult men during critical periods of their life may be the key to reducing rates of cardiovascular disease. 

STS late-breaking study found BITA and SITA+RA have similar long-term survival, but age plays a role in which to choose.

Patients with this specific subtype of severe aortic stenosis, which can sometimes be challenging to diagnose, face a number of additional risks.

More and more imaging researchers are starting to examine the potential of using fibroblast activation protein inhibitors (FAPI) to manage patients with suspected cardiovascular disease.

The BENEFIT-HF trial, scheduled to begin enrollment in the months ahead, could significantly increase the number of patients eligible for CVRx's Barostim therapy.

Shockwave Medical, now a part of Johnson & Johnson MedTech, sits at the top of the IVL market, but things are starting to get more competitive. Boston Scientific gained its own IVL system when it acquired Bolt Medical in 2025.

Gene-editing drugs have shown potential to treat a wide variety of diseases, and this will be one of the first in cardiovascular medicine to begin human trials.